Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):910–916. doi: 10.1128/aac.39.4.910

Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus.

Y Sumita 1, H Nouda 1, K Kanazawa 1, M Fukasawa 1
PMCID: PMC162652  PMID: 7785994

Abstract

The in vitro and in vivo antibacterial activities of SM-17466, a new 1 beta-methyl carbapenem, were evaluated against a wide range of clinical bacterial isoaltes and compared with the activities of meropenem, imipenem, vancomycin, and arbekacin. SM-17466 had a broad spectrum of action against gram-positive bacteria, showing especially potent activity against methicillin-resistant staphylococci. The MICs of SM-17466, meropenem, imipenem, vancomycin, and arbekacin at which 90% of clinical isolates of methicillin-resistant Staphylococcus aureus were inhibited were 3.13, 50, 100, 1.56, and 3.13 micrograms/ml, respectively. This activity of SM-17466 was almost equivalent to those of the antibiotics used for the treatment of infections caused by this organism. SM-17466 also showed bactericidal activity against methicillin-resistant S. aureus. In contrast, SM-17466 was less active against gram-negative bacteria, especially against Pseudomonas aeruginosa, compared with the other carbapenems; however, of the carbapenems, SM-17466 exhibited the highest activity against Haemophilus influenzae and Bacteriodes fragilis. SM-17466, at a 50% inhibitory concentration of less than 1 microgram/ml, bound to penicillin-binding proteins 1 to 4 in methicillin-susceptible S. aureus and also had good binding to penicillin-binding protein 2' in a methicillin-resistant strain (50% inhibitory concentration, 5.9 micrograms/ml). This high affinity, which was 10 and 20 times greater than those for meropenem and imipenem, respectively, was reflected in the potent activity of SM-17466 against methicillin-resistant S. aureus. SM-17466 demonstrated excellent in vivo efficacy against methicillin-susceptible and -resistant S. aureus strains in a mouse peritoneal infection model: the efficacy of SM-17466 against methicillin-resistant strains was equal to or one-third that of vancomycin. This activity was comparable to the in vitro activity of SM-17466. The subcutaneous injection of SM-17466 in mice revealed that the half-life of SM-17466 in serum was about 18 min, intermediate between those of vancomycin and arbekacin and 1.5-fold that of imipenem-cilastatin. SM-17466 was resistant to hydrolysis by swine renal dehydropeptidase I, to an extent comparable to the resistance shown by meropenem.

Full Text

The Full Text of this article is available as a PDF (238.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger-Bächi B., Strässle A., Kayser F. H. Characterization of an isogenic set of methicillin-resistant and susceptible mutants of Staphylococcus aureus. Eur J Clin Microbiol. 1986 Dec;5(6):697–701. doi: 10.1007/BF02013308. [DOI] [PubMed] [Google Scholar]
  2. Catchpole C. R., Wise R., Thornber D., Andrews J. M. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother. 1992 Sep;36(9):1928–1934. doi: 10.1128/aac.36.9.1928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Edwards J. R., Turner P. J., Wannop C., Withnell E. S., Grindey A. J., Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1989 Feb;33(2):215–222. doi: 10.1128/aac.33.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fukasawa M., Sumita Y., Harabe E. T., Tanio T., Nouda H., Kohzuki T., Okuda T., Matsumura H., Sunagawa M. Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother. 1992 Jul;36(7):1577–1579. doi: 10.1128/aac.36.7.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fukuoka T., Ohya S., Narita T., Katsuta M., Iijima M., Masuda N., Yasuda H., Trias J., Nikaido H. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother. 1993 Feb;37(2):322–327. doi: 10.1128/aac.37.2.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kondo S., Iinuma K., Yamamoto H., Maeda K., Umezawa H. Letter: Syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot (Tokyo) 1973 Jul;26(7):412–415. doi: 10.7164/antibiotics.26.412. [DOI] [PubMed] [Google Scholar]
  7. Nakagawa S., Hashizume T., Matsuda K., Sanada M., Okamoto O., Fukatsu H., Tanaka N. In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity. Antimicrob Agents Chemother. 1993 Dec;37(12):2756–2759. doi: 10.1128/aac.37.12.2756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neu H. C., Chin N. X., Saha G., Labthavikul P. In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem. Antimicrob Agents Chemother. 1986 Dec;30(6):828–834. doi: 10.1128/aac.30.6.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Saravolatz L. D., Pohlod D. J., Arking L. M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med. 1982 Sep;97(3):325–329. doi: 10.7326/0003-4819-97-3-325. [DOI] [PubMed] [Google Scholar]
  10. Spratt B. G. Properties of the penicillin-binding proteins of Escherichia coli K12,. Eur J Biochem. 1977 Jan;72(2):341–352. doi: 10.1111/j.1432-1033.1977.tb11258.x. [DOI] [PubMed] [Google Scholar]
  11. Sumita Y., Fukasawa M., Okuda T. Affinities of SM-7338 for penicillin-binding proteins and its release from these proteins in Staphylococcus aureus. Antimicrob Agents Chemother. 1990 Mar;34(3):484–486. doi: 10.1128/aac.34.3.484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sumita Y., Inoue M., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):908–916. doi: 10.1007/BF01963782. [DOI] [PubMed] [Google Scholar]
  13. Sunagawa M., Matsumura H., Fukasawa M. Structure-activity relationships of carbapenem and penem compounds for the convulsive property. J Antibiot (Tokyo) 1992 Dec;45(12):1983–1985. doi: 10.7164/antibiotics.45.1983. [DOI] [PubMed] [Google Scholar]
  14. Ubukata K., Hikida M., Yoshida M., Nishiki K., Furukawa Y., Tashiro K., Konno M., Mitsuhashi S. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother. 1990 Jun;34(6):994–1000. doi: 10.1128/aac.34.6.994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wenzel R. P. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):440–442. doi: 10.7326/0003-4819-97-3-440. [DOI] [PubMed] [Google Scholar]
  16. Yoshida M., Mitsuhashi S. In vitro antibacterial activity and beta-lactamase stability of the new carbapenem LJC10,627. Eur J Clin Microbiol Infect Dis. 1990 Aug;9(8):625–629. doi: 10.1007/BF01967222. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES